PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-143.14%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
5.86%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
-142.73%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-120.58%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-120.58%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
10.21%
Share count expansion well above AVXL's 11.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.21%
Diluted share count expanding well above AVXL's 11.00%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
9.39%
OCF growth above 1.5x AVXL's 3.29%. David Dodd would confirm a clear edge in underlying cash generation.
9.37%
FCF growth above 1.5x AVXL's 3.29%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56347.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-5186.83%
Negative 5Y OCF/share CAGR while AVXL is at 76.58%. Joel Greenblatt would question the firm’s operational model or cost structure.
-34380.15%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-67208.18%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-8163.79%
Negative 5Y net income/share CAGR while AVXL is 63.05%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-121.82%
Negative 3Y CAGR while AVXL is 9.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
31995.75%
Equity/share CAGR of 31995.75% while AVXL is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
9371.92%
5Y equity/share CAGR above 1.5x AVXL's 130.73%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
10880.98%
3Y equity/share CAGR above 1.5x AVXL's 176.62%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
28.45%
Under 50% of AVXL's 795.42%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-51.38%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-5.21%
Our R&D shrinks while AVXL invests at 27.78%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-6.73%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.